With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387 ...

Recombinant human Hyaluronidase PH20 (rHuPH20) is an enzyme that degrades subcutaneous ... of infliximab, PK of infliximab was analyzed after SC injection along with HyDIFFUZETM and compared with that ...

Here are some tips to help you navigate insulin dosing at meal times ... This is referred to as a subcutaneous injection. If you inject the insulin too deep and it enters your muscle, your ...

You’ll receive Syfovre injections at your doctor’s office. The usual recommended dosage is 15 mg injected into the affected eye every 25 to 60 days. Your doctor will determine how often you ...

The U.S. Food and Drug Administration has approved a self ... The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver ...

This new research confirmed earlier findings showing that the experimental drug — lepodisiran ... receive either a placebo or one or two subcutaneous injections of lepodisiran.

After one injection of the highest dose, participants showed a nearly 100% reduction in levels of lipoprotein(a) at six months. Those who received a second dose at six months maintained an almost ...

Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. The single-dose ...

Patients can self-inject after proper instruction in subcutaneous injection technique. The single-dose prefilled subcutaneous injection was developed as part of argenx’s exclusive partnership with ...

In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...